The source article reports the long-term follow-up of JCOG1008, a randomized Phase II/III clinical trial that compared two cisplatin dosing schedules—3-weekly cisplatin versus weekly cisplatin—when given concurrently with radiotherapy as postoperative chemoradiotherapy for patients with head and neck cancer. The study title, trial designation (JCOG1008), and the central comparison of dosing frequency are explicitly stated in the source metadata.
From the information provided in the source excerpt, the trial is described as randomized and Phase II/III, indicating a design intended to evaluate both preliminary and confirmatory clinical outcomes for the two concurrent chemoradiotherapy regimens. The two arms compared are identified only by dosing schedule: a 3-weekly cisplatin regimen and a weekly cisplatin regimen delivered with radiotherapy in the postoperative setting for head and neck cancer.
The source metadata does not include specific procedural details such as total radiotherapy dose or fractionation, cisplatin dose per administration, number of planned cycles, eligibility criteria, stratification factors, primary and secondary endpoints, sample size, or duration of follow-up. Those protocol-level details and operational parameters were not reported in the provided excerpt.
The manuscript lists Makoto Tahara and Naomi Kiyota among the lead authors and includes a long multi-author byline representing investigators from numerous Japanese institutions. The work is associated with the Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG), and a collaborator list is provided in the source metadata.
Affiliations named in the source include, among others, National Cancer Center Hospital East (Kashiwa), Kobe University Hospital Cancer Center (Kobe), Aichi Cancer Center Hospital (Nagoya), Jichi Medical University Hospital (Shimotsuke), Miyagi Cancer Center (Natori), Cancer Institute Hospital (Tokyo), Hyogo Cancer Center (Akashi), Shizuoka Cancer Center (Shizuoka), Nagoya University Hospital (Nagoya), and many additional centers and university hospitals across Japan. The full affiliations list enumerates 29 distinct institutional entries in the source record.
This report is published in Journal of Clinical Oncology (J Clin Oncol). The bibliographic identifiers in the source are:
The source record provides links to full-text access, including a free PMC article link, and a link to the publisher (Atypon) full-text options.
The provided source excerpt contains metadata, authorship, affiliations, publication and access information, and the clinical trial designation, but it does not contain the trial’s numerical results, comparative efficacy outcomes, survival or recurrence data, toxicity and adverse event profiles, statistical analyses, or the authors’ conclusions. Specifics such as patient numbers randomized, median follow-up duration, primary endpoint results, hazard ratios, p values, and safety outcomes were not reported in the source text provided here.
Where outcome details are required for clinical interpretation or guideline implications, readers should consult the full text available via the PMC link or journal site; the source excerpt itself does not supply outcome data.
The article is clearly identified as a clinical trial and highlights a direct clinical comparison of dosing schedules for cisplatin in the postoperative management of head and neck cancer. The full-text article is accessible through PubMed Central (PMC), and the record supplies standard bibliographic identifiers to facilitate retrieval. The collaborative nature of the trial is emphasized by the long author list and the involvement of the JCOG Head and Neck Cancer Study Group.
Note: This rewritten summary is limited to information present in the PubMed/NCBI source excerpt. Trial results, numerical outcomes, and specific clinical conclusions were not included in the provided text and therefore are not reported here. For complete outcome data and the authors’ analyses, refer to the full-text article via the supplied DOI or PMCID links.